GLAXOSMITHKLINE PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,631 INR | +1.45% |
|
+8.24% | +38.64% |
| Sales 2024 | 34.54B 414M | Sales 2025 * | 37.99B 455M | Capitalization | 446B 5.34B |
|---|---|---|---|---|---|
| Net income 2024 | 5.9B 70.74M | Net income 2025 * | 8.18B 98.02M | EV / Sales 2024 | 9.53 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 11.7 x |
| P/E ratio 2024 |
55.8
x | P/E ratio 2025 * |
54.5
x | Employees | 3,680 |
| Yield 2024 |
1.65% | Yield 2025 * |
1.15% | Free-Float | 24.42% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +1.45% | ||
| 1 week | +8.24% | ||
| 1 month | +26.04% | ||
| 3 months | +21.11% | ||
| 6 months | +58.86% | ||
| Current year | +38.64% |
1 week
2 355.15
2 652.15
1 month
1 965.002 652.15
Current year
1 825.052 652.15
1 year
1 306.802 652.15
3 years
1 228.002 652.15
5 years
1 046.402 652.15
10 years
1 020.002 652.15
| Managers | Title | Age | Since |
|---|---|---|---|
Bhushan Akshikar
CEO | Chief Executive Officer | 54 | 22-11-30 |
Juby Chandy
DFI | Director of Finance/CFO | - | 22-03-31 |
Simrat Sohal
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Renu Sud Karnad
CHM | Chairman | 70 | 19-03-31 |
Manu Anand
BRD | Director/Board Member | 64 | 22-05-15 |
| Director/Board Member | 74 | 15-03-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 112 M€ | +4.61% | - | |
| 0.00% | 32 M€ | +6.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 2,631 | +1.45% | 12,745 |
| 24-05-30 | 2,593 | +2.22% | 18,883 |
| 24-05-29 | 2,537 | +2.09% | 27,108 |
| 24-05-28 | 2,485 | +5.40% | 15,196 |
| 24-05-27 | 2,358 | -3.00% | 26,394 |
Delayed Quote Bombay S.E., May 31, 2024 at 06:26 am EDT
More quotes
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
Sector
Pharmaceuticals
Calendar
2024-06-28
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2,631
INR
Average target price
2,598
INR
Spread / Average Target
-1.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.64% | 5.34B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- GLAXO Stock
